BioCentury
ARTICLE | Company News

Microbiome companies Finch and Crestovo merge

October 23, 2017 10:50 PM UTC

Microbiome companies Crestovo LLC (Cambridge, Mass.) and Finch Therapeutics Inc. (Somerville, Mass.) merged to form Finch Therapeutics Group (Somerville, Mass.), which will focus on developing oral alternatives to fecal microbiota transplant.

Crestovo's lead candidate, CP101, is in the Phase II PRISM 3 trial to prevent recurrent Clostridium difficile infection (CDI) with top-line data expected in 2018. The company developed the microbiome therapy with its Full-Spectrum Microbiota platform, which delivers most of the microbial communities present in donor microbiomes...